Organon Reports Positive Phase 3 VTAMA Data in Atopic Dermatitis
JERSEY CITY, N.J., July 24, 2026 Organon (NYSE: OGN) presented new post hoc pooled Phase 3 data from the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
JERSEY CITY, N.J., July 24, 2026 Organon (NYSE: OGN) presented new post hoc pooled Phase 3 data from the...
Jersey City, New Jersey, U.S. | April 15, 2026 Organon has announced that its VTAMA® (tapinarof) cream, 1% has...
